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Background: Trastuzumab prolongs survival of human epidermal growth factor receptor 2-positive breast cancer
patients in both the adjuvant and metastatic settings. Currently toxicity data are not available on retreatment of
metastatic breast cancer patients who relapse after adjuvant trastuzumab. We report one patient with metastatic
breast cancer who developed acute thrombocytopenia after trastuzumab infusion. This patient had trastuzumab
treatment in the adjuvant setting.
Case presentation: A 70-year-old Caucasian woman received a diagnosis of metastatic breast cancer four years
after her initial diagnosis of locally advanced, hormone receptors-positive, human epidermal growth factor receptor
2-positive breast cancer. Trastuzumab retreatment was planned. Less than 24 hours after trastuzumab infusion, the
patient was admitted to the hospital for the appearance of diffuse petechial hemorrhages and ecchymosis. The
patient was confirmed to have a severe trastuzumab-induced thrombocytopenia. A rapid and complete recovery
was observed after high-dose intravenous corticosteroids and immunoglobulin. No trastuzumab retreatment was
attempted.
Conclusion: Among the reported cases of trastuzumab-induced thrombocytopenia, this is the first report in the
literature occurring in a patient retreated with trastuzumab after adjuvant therapy.
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Trastuzumab is a humanized monoclonal antibody di-
rected against the human epidermal growth factor re-
ceptor 2 (HER2). The combination of trastuzumab with
chemotherapy has been shown to improve survival in
both the metastatic and adjuvant settings [1-5]. Myelo-
suppression is rare and generally mild after trastuzumab
treatment [6,7]. Nevertheless, five cases of trastuzumab-
related thrombocytopenia have been reported to date
[8-12]. In four cases a quick and sustained recovery of
platelet count after high-dose intravenous corticosteroids
and immunoglobulin was observed. Yet, a patient ma-
nifested a chronic evolution of thrombocytopenia, with
refractoriness to immunosuppressive treatment. Among
the reported cases of trastuzumab-induced severe throm-
bocytopenia, only one patient, in the adjuvant setting, did
not interrupt trastuzumab. Currently, no toxicity data are
available on retreatment with trastuzumab after relapse* Correspondence: mariasimona.pino@asf.toscana.it
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reproduction in any medium, provided the orfollowing adjuvant trastuzumab. Here, we describe a case
of acute thrombocytopenia in one patient with metastatic
breast cancer, which received trastuzumab several years
after its adjuvant use.
Case presentation
A 70-year-old Caucasian woman was diagnosed with
locally advanced hormone receptors-positive, HER2-
positive breast cancer in 2008. She received neoadjuvant
chemotherapy with a sequential anthracyclines-taxane
regimen, surgery and radiotherapy. After surgery the pa-
tient received adjuvant anastrozole and trastuzumab, as
per the HERceptin Adjuvant (HERA) trial [2]. Follow-up
was negative until July 2012 when imaging demonstrated
an extended bone relapse. A second line treatment with
trastuzumab and oral vinorelbine was planned. The day
of her loading dose (8 mg/kg of trastuzumab) full blood
count was within normal limits Figure 1. She did not
receive any heparin (either as treatment or flush), and
the infusion of trastuzumab was uneventful. Less than
24 hours after the infusion, the patient turned to thed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Platelet counts before and after trastuzumab therapy. Left y-axis represents platelet counts and X-axis represents days before and
after the treatment.
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hemorrhages and ecchymosis on the lower extremities,
lips and buccal mucosa. She was afebrile and cardio-
vascularly stable. The platelet count was 2000/mm3, with
normal hemoglobin and leukocyte count, and negligible
routine biochemistry and clotting. After 6 hours fromFigure 2 Six days after trastuzumab infusion, a pruriginous skin ecze
induction of specific anti-idiotype antibodies.admittance, platelet count was 0/mm3. High-dose im-
mune globulin (1 g per kilogram given intravenously in
24 hours, for 5 days), methylprednisolone (1 g per
kilogram given intravenously for 7 days), and platelet
transfusions were administered. The patient’s prior
medical history was unremarkable. Other causes ofma with a generalized rash was observed, attributed to the
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clotting, D-dimers, immunoglobulins, renal function,
bilirubin and lactate dehydrogenase as well as lack of
schistocytes on blood smear and normal activity of the
disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 (ADAMTS-13). After 12 hours
from admittance the platelet count started recovering. Six
days after receiving trastuzumab, a pruriginous skin ec-
zema with generalized rashes was observed, attributed to
the induction of specific anti-idiotype antibodies Figure 2.
The rash resolved spontaneously within 48 hours. The pa-
tient was discharged by day 13 with low dose oral prednis-
one. No trastuzumab retreatment was attempted.
Conclusions
Diagnosis of drug-induced immune thrombocytopenia is
usually made by exclusion. In our case, based on the
clinical criteria and level of evidence elaborated by
George and colleagues, the causative relationship was
considered probable [13]. Indeed, treatment with trastu-
zumab preceded thrombocytopenia, recovery was com-
pleted and sustained after its discontinuation, and other
causes of thrombocytopenia were excluded. We hypo-
thesize that thrombocytopenia was related to preexisting
drug-specific antibodies recognizing murine component
of chimeric Fab fragment specific for platelet membrane
glycoprotein IIIa. Clearance of the antibody-coated plate-
lets by the mononuclear phagocytic system would be the
ultimate cause of the severe thrombocytopenia. On the
basis of our observation, trastuzumab retreatment calls
for prudence.
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